MediPharm Labs Corp. (MEDIF) Q1 2024 Earnings Call Transcript


MediPharm Labs Corp. (OTCQB:MEDIF) Q1 2024 Earnings Conference Call May 15, 2024 8:30 AM ET

Company Participants

David Pidduck – CEO
Keith Strachan – President
Greg Hunter – CFO

Conference Call Participants

Remington Smith – Alliance Global Partners

Operator

Ladies and gentlemen, thank you for standing by and welcome to the MediPharm Labs 2024 First Quarter Financial Results Conference Call. Please be advised that today’s conference call is being recorded.

Before we begin, please note that remarks today may contain forward-looking information and forward-looking statements within the meaning of applicable security laws. This includes, without limitation, statements about MediPharm Labs and its current and future plans, expectations, intentions, financial results, levels of activity, performance, goals or achievements and other future events, trends, profitability, business growth or development. Forward-looking statements are made as of the date hereof based on information currently available to management of MediPharm and on estimates and assumptions made based on factors that MediPharm believes are appropriate and reasonable in the circumstances. However, there can be no assurance that such estimates and assumptions will prove to be correct. Any factors could cause actual results to differ materially from those expressed or implied by forward-looking statements. Additional information is contained in MediPharm Labs’ filings with the Canadian and Provincial Security Regulators which are available on SEDAR at sedar.com.

The company’s remarks may also contain references to certain non-IFRS financial measures, including EBITDA, adjusted EBITDA, gross profit and actual gross profit. These measures do not have any standardized meanings according to the International Financial Reporting Standards or IFRS and therefore, may not be comparable to similar measures presented by other companies. MediPharm believes that the non-IFRS measures reference provide information useful to shareholders and investors in understanding our performance and may assist in the evaluation of the combined company’s business relative to that of its peers. For



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *